|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.15 USD | +0.79% |
|
+4.25% | +8.56% |
| 16/06 | Zai Lab Receives EU Orphan Drug Designation for Lung Cancer Drug | MT |
| 10/06 | Asian Equities Traded in the US as American Depositary Receipts Lower in Wednesday Trading | MT |
| Market Cap | 215.16Cr 188.91Cr 173.88Cr 162.03Cr 305.58Cr 20TCr 311.79Cr 2.09TCr 810.31Cr 10TCr 807.86Cr 790.39Cr 35TCr | P/E 2026 * |
-8.65x | P/E 2027 * | -10.3x |
|---|---|---|---|---|---|
| Enterprise Value | 170.85Cr 150Cr 138.07Cr 128.66Cr 242.64Cr 16TCr 247.57Cr 1.66TCr 643.43Cr 7.97TCr 641.48Cr 627.61Cr 28TCr | EV / Sales 2026 * |
3.81x | EV / Sales 2027 * | 2.96x |
| Free-Float |
95.17% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Zai Lab Limited
| 1 day | +0.79% | ||
| 1 week | +4.25% | ||
| Current month | +0.79% | ||
| 1 month | +12.05% | ||
| 3 months | -5.85% | ||
| 6 months | +8.56% | ||
| Current year | +8.56% |
| 1 week | 17.23 |  | 19.61 |
| 1 month | 16.26 | | 19.61 |
| Current year | 15.96 | | 25.28 |
| 1 year | 15.96 | | 41.2 |
| 3 years | 13.48 | | 44.34 |
| 5 years | 13.48 | | 176.17 |
| 10 years | 13.48 | | 193.54 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ying Du
CEO | Chief Executive Officer | 60 | 01/04/2014 |
Ya jing Chen
DFI | Director of Finance/CFO | 58 | 07/07/2023 |
Rafael Amado
PSD | President | 62 | 01/12/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Ying Du
CHM | Chairman | 60 | 01/04/2014 |
John Diekman
BRD | Director/Board Member | 82 | 01/01/2017 |
Peter Wirth
BRD | Director/Board Member | 74 | 01/01/2017 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 26/06 | Other | Chief Executive Officer | -2,45,430 | 0.0216% | ||
| 26/06 | Sell | Chief Financial Officer | -2,264 | 0.0002% | ||
| 26/06 | Sell | General Counsel | -4,103 | 0.0004% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.79% | +4.25% | -45.55% | -30.94% | 215.16Cr | |
| +0.19% | +0.21% | +16.79% | -13.06% | 6.36TCr | |
| +0.23% | +0.74% | +55.07% | +225.08% | 5.59TCr | |
| +0.36% | +39.60% | +39.60% | +39.60% | 4.17TCr | |
| -0.52% | +0.08% | -50.89% | -57.38% | 3.91TCr | |
| -2.93% | +5.09% | +61.25% | -26.37% | 3.1TCr | |
| +3.53% | +19.99% | +152.70% | -40.33% | 2.88TCr | |
| +0.40% | +4.93% | +65.59% | +82.83% | 2.27TCr | |
| +7.16% | +12.09% | +7.57% | +184.33% | 1.76TCr | |
| +0.53% | -0.17% | +64.40% | +125.36% | 1.67TCr | |
| Average | +0.98% | +4.63% | +36.65% | +48.91% | 3.19TCr | |
| Weighted average by Cap. | +0.55% | +3.82% | +39.77% | +51.20% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 45Cr 39Cr 36Cr 34Cr 64Cr 4.27TCr 65Cr 436.14Cr 168.98Cr 2.09TCr 168.47Cr 164.83Cr 7.29TCr | 60Cr 52Cr 48Cr 45Cr 85Cr 5.66TCr 86Cr 578.91Cr 224.3Cr 2.78TCr 223.62Cr 218.78Cr 9.67TCr |
| Net income | -24Cr -21Cr -19Cr -18Cr -34Cr -2.29TCr -35Cr -234.16Cr -91Cr -1.12TCr -90Cr -88Cr -3.91TCr | -16Cr -14Cr -13Cr -12Cr -22Cr -1.49TCr -23Cr -152.09Cr -59Cr -730.2Cr -59Cr -57Cr -2.54TCr |
| Net Debt | -44Cr -39Cr -36Cr -33Cr -63Cr -4.21TCr -64Cr -430.73Cr -166.89Cr -2.07TCr -166.38Cr -162.78Cr -7.2TCr | -39Cr -34Cr -31Cr -29Cr -55Cr -3.68TCr -56Cr -376.36Cr -145.82Cr -1.81TCr -145.38Cr -142.23Cr -6.29TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 01/26/01 | $19.15 | +0.79% | 6,86,357 |
| 30/26/30 | $19.00 | +3.20% | 7,54,802 |
| 29/26/29 | $18.41 | +2.28% | 9,44,910 |
| 26/26/26 | $18.00 | -2.81% | 18,55,223 |
| 25/26/25 | $18.52 | +0.82% | 7,17,203 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ZLAB Stock
Select your edition
All financial news and data tailored to specific country editions
